Taken together, these data demonstrate that RAGE signalling activation is responsible for the SHP-2 mediated monocyte activation in the T2DM environment and that the blockade of RAGE is sufficient to attenuate SHP-2-dependent monocyte activation. Here, AGER is linked to type 2 diabetes mellitus.